Oprymea is a medicine used to treat the symptoms of the following diseases: - Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Oprymea can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective; - moderate to severe restless-legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night. Oprymea is used when a specific cause for the disorder cannot be identified. Oprymea contains the active substance pramipexole. Oprymea is a ‘generic medicine’. This means that Oprymea contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Sifrol (also known as Mirapexin).
Therapeutic Indication
### Therapeutic indication Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations). Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).
Therapeutic Area (MeSH)
N/AATC Code
N04BC05
ATC Item
pramipexole
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| pramipexole dihydrochloride monohydrate | N/A | 普拉克索 |
EMA Name
Oprymea
Medicine Name
Oprymea
Aliases
N/ANo risk management plan link.